|
|
 |
|
Viewing report
|
|
|
|
Kuwait Pharmaceuticals and Healthcare Report Q3 2009
Business Monitor International, June 2009, Pages: 77
Kuwait Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulartory bodies with independent forecasts and competitive intelligence on Kuwait's pharmaceutical and healthcare industry
Kuwait’s pharmaceutical market is small in regional terms. Combined sales of over-the-counter (OTC) and prescription drugs reached a total of US$377mn in 2008, and we expect this to reach US$462mn by 2013 – representing a compound annual growth rate (CAGR) of 4.17% in US dollar terms.
Pharmaceutical spending will account for 0.27% of GDP, with per capita expenditure at US$136 by the end of the forecast period. We expect growth to be driven by the strong bias toward patented drugs, which still dominate the market.
With little or no enforced incentives for prescribers or dispensers to substitute for generics where possible, this looks likely to continue in the medium term. However, we note that import policies in the region have all been affected by unfavourable currency fluctuations against the euro when procuring EU medicines. We note that the Kuwaiti government is not actively encouraging a domestic manufacturing industry, which restricts choices on imports and in addition means the country is heavily reliant on those medicines.
BMI’s Burden of Disease Database (BoDD) reveals that the number of disability-adjusted life years (DALYs) lost to communicable diseases in Kuwait will decrease from 29,836 in 2008 to 24,888 by 2030. Meanwhile, the DALYs lost to non-communicable disease will rise from 190,740 in 2008 to 258,306 by 2030. The main driver for this growth is attributed to the rise in obesity and obesity-related disorders including hypertension, diabetes, and cardiovascular disease.
We note that chronic conditions pose a significant burden on healthcare services and directly lead to a rise in prescription medication spending. This makes the patented drug market in these therapeutic areas particularly attractive to multinational drugmakers looking for new export destinations in the Middle East. Generic drugs are slowly gaining market share, though government policy on substitution needs to be drafted and implemented to encourage further growth in this sector.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Kuwait Pharmaceuticals and Healthcare Report Q1 2009
Kuwait Pharmaceuticals and Healthcare Report Q4 2011
Kuwait Pharmaceuticals and Healthcare Report Q2 2009
Kuwait Pharmaceuticals and Healthcare Report Q4 2009
Kuwait Pharmaceuticals and Healthcare Report Q3 2011
Kuwait Pharmaceuticals and Healthcare Report Q3 2008
Kuwait Pharmaceuticals and Healthcare Report Q4 2010
Estonia Pharmaceuticals and Healthcare Report Q1 2011
Kuwait Pharmaceuticals and Healthcare Report Q2 2010
Kuwait Pharmaceuticals and Healthcare Report Q1 2010
|
|
|
|
